Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study.

摘要: Prognosis of acquired immunodeficiency syndrome (AIDS)–related non-Hodgkin lymphoma has improved since the introduction highly active antiretroviral therapy. Burkitt lymphomas (BLs) still have poor outcome in patients with bone marrow (BM) or central nervous system (CNS) involvement when treated standard-dose chemotherapy. We prospectively evaluated LMB86 regimen 63 human virus (HIV)–infected stage IV (BM and/or CNS involvement) BL consecutively recruited between November 1992 and January 2006. At diagnosis, median CD4 cell count was 239 × 106/L (range, 16-1188 106/L). BM were present 55 (80%) 48 (76%) patients, respectively. Forty-four (70%) achieved complete response. Seven treatment-related deaths occurred all experienced severe toxicity. With a follow-up 66 months 6-165 months), 11 relapsed. The estimate 2-year overall survival disease-free 47.1% (95% CI, 34-59.1) 67.8% 51-80), identified 2 prognosis factors: low ECOG more than 2. Patients 0 1 factor had good (2-year survival: 60%) contrasting factors 12%). conclude that is effective advanced HIV-related should be proposed for higher 200 less.